Treatment of cystic macular lesions in hereditary retinal dystrophies

Survey of Ophthalmology

Volumn 58, Issue 6, 2013, Pages 560-584

  Salvatore, Serena ^a,b   Fishman, Gerald A ^b,c   Genead, Mohamed A ^b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Pangere Center for Hereditary Retinal Diseases   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Choroideremia; Cystoid macular lesions; Enhanced S cone syndrome; Goldmann Favre syndrome; Gyrate atrophy; Hereditary retinal dystrophies; Retinitis pigmentosa; X linked retinoschisis

Indexed keywords

ACETAZOLAMIDE; BEVACIZUMAB; CARBONATE DEHYDRATASE INHIBITOR; CORTICOSTEROID; DEFLAZACORT; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL MALEATE; METHAZOLAMIDE; PEGAPTANIB; PLACEBO; RANIBIZUMAB; RETINOSCHISIN; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; XANTHOPHYLL;

ANEMIA; BLOOD RETINA BARRIER; CHOROID GYRATE ATROPHY; CHOROIDEREMIA; CHRONIC DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; ENHANCED S CONE SYNDROME; FATIGUE; GENE FUNCTION; GENE MUTATION; HEREDITARY RETINAL DYSTROPHY; HUMAN; JUVENILE ONSET X LINKED RETINOSCHISIS; LASER COAGULATION; LIMB DISEASE; LOSS OF APPETITE; MUTATOR GENE; NEPHROLITHIASIS; NONHUMAN; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PARESTHESIA; PATHOGENESIS; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA DYSTROPHY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA GYRATE ATROPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINAL THICKNESS; RETINITIS PIGMENTOSA; RETINOSCHISIN GENE; RETINOSCHISIS; REVIEW; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; USHER SYNDROME; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY;

CHOROIDEREMIA; CYSTOID MACULAR LESIONS; ENHANCED S-CONE SYNDROME; GOLDMANN-FAVRE SYNDROME; GYRATE ATROPHY; HEREDITARY RETINAL DYSTROPHIES; RETINITIS PIGMENTOSA; X-LINKED RETINOSCHISIS;

CARBONIC ANHYDRASE INHIBITORS; CHOROIDEREMIA; EYE DISEASES, HEREDITARY; GYRATE ATROPHY; HUMANS; MACULAR EDEMA; RETINAL DEGENERATION; RETINITIS PIGMENTOSA; RETINOSCHISIS; VISION DISORDERS;

EID: 84886240183     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2012.11.006     Document Type: Review

References (203)

1. Adackapara C.A., Sunness J.S., Dibernardo C.W., et al. Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial. Retina 2008, 28:103-110.
2. Affortit-Demoge A., Querques G., Angulo-Bocco C., et al. Optical coherence tomography features of x-linked choroideremia. Retinal Cases Brief Rep 2009, 3:180-182.
3. Andres D.A., Seabra M.C., Brown M.S., et al. cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein. Cell 1993, 73:1091-1099.
4. Apushkin M.A., Fishman G.A. Use of dorzolamide for patients with X-linked retinoschisis. Retina 2006, 26:741-745.
5. Apushkin M.A., Fishman G.A., Grover S., et al. Rebound of cystoid macular edema with continued use of acetazolamidein patients with retinitis pigmentosa. Retina 2007, 27:1112-1118.
6. Apushkin M.A., Fishman G.A., Janowicz M.J. Monitoring cystoid macular edema by optical coherence tomography in patients with retinitis pigmentosa. Ophthalmology 2004, 111:1899-1904.
7. Aturnay O., Yuzbasioglu E., Rasier R., et al. Intravitreal ranibizumab in the treatment of macular edema associated with retinitis pigmentosa. JOcul Pharmacol Ther 2009, 25:545-550.
8. Audo I., Michaelides M., Robson A.G., et al. Phenotypic variation in enhanced S-cone syndrome. Invest Ophthalmol Vis Sci 2008, 49:2082-2093.
9. Azzolini C., Pierro L., Codenotti M., et al. OCT images and surgery of juvenile macular retinoschisis. Eur J Ophthalmol 1997, 7:196-200.
10. Bahrami H., Melia M., Dagnelie G. Lutein supplementation inretinitis pigmentosa: PC-based vision assessment ina randomized double-masked placebo-controlled clinicaltrial[NCT00029289]. BMC Ophthalmol 2006, 6:23.
11. Bastos A.L., Freitas B.P., Villas B.O., et al. Use of topical dorzolamide for patients with X-linked juvenile retinoschisis: case report. Arq Bras Oftalmol 2008, 71:286-290.
12. Behbehani M.M., Bowyer D.W., Ruffolo J.J., et al. Preservation of retinal function in the RCS rat by laser treatment. Retina 1984, 4:257-263.
13. Beighton P., Beighton G. The man behind the syndrome 1986, Springer-Verlag, Berlin, p 177.
14. Berson E.L. Retinitis pigmentosa: the Friedenwald Lecture. Invest Ophthamol Vis Sci 1993, 34:1659-1676.
15. Biollaz J., Munafo A., Buclin T., et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 1995, 47:455-460.
16. Bonnet C., El-Amraoui A. Usher syndrome (sensorineural deafness and retinitis pigmentosa): pathogenesis, molecular diagnosis and therapeutic approaches. Curr Opin Neurol 2012, 25:42-49.
17. Bowles K., Cukras C., Turriff A., et al. X-Linked retinoschisis:RS1 mutation severity and age affect the ERG phenotype in a cohort of 68 affected male subjects. Invest Ophthalmol Vis Sci 2011, 52:9250-9256.
18. Brown D.M., Heier J.S., Ciulla T., et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmol 2011, 118:1089-1097.
19. Caldwell R.B., McLaughlin B.J., Boykins L.G. Intramembrane changes in retinal pigment epithelial cell junctions of the dystrophic rat retina. Invest Ophthalmol Vis Sci 1982, 23:305-318.
20. Chant S.M., Heckenlively J.R., Meyers-Elliott R.H. Autoimmunity in hereditary retinal degeneration, I: basic studies. Br J Ophthalmol 1985, 69:19-24.
21. Charbel-Issa P., Troeger E., Finger R., et al. Structure-functioncorrelation of the human central retina. PLoS 2010, 5:e12864.
22. Chen F., Figueroa D.J., Marmorstein A.D., et al. Retina-specific nuclear receptor: a potential regulator of cellular retinaldehyde-binding protein expressed in retinal pigment epithelium and Müller glial cells. Proc Natl Acad Sci USA 1999, 96:15149-15154.
23. Chen J.C., Firzke F.W., Bird A.C. Long-term effect of acetazolamide in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci 1990, 31:1914-1918.
24. Condon G.P., Brownstein S., Wang N.S., et al. Congenital hereditary (juvenile X-linked) retinoschisis. Histopathologic and ultrastructural findings in three eyes. Arch Ophthamol 1986, 104:576-583.
25. Coscas G., Gaudric A. Natural course of nonaphakic cystoid macular edema. Surv Ophthalmol 1984, 28(Suppl)):471-484.
26. Cox S.N., Hay E., Bird A.C. Treatment of chronic macular edema with acetazolamide. Arch Ophthamol 1988, 106:1190-1195.
27. De Jong P.T., Zrenner E., van Meel G.J., et al. Mizuo phenomen in X-linked retinoschisis. Pathogenesis of Mizuo phenomen. Arch Ophthalmol 1991, 109:1104-1108.
28. De La Chapelle A., Alitalo T., Forsius H. X-linked juvenile retinoschisis. Molecular Genetics of Inherited Eye Disorders 1994, 339-357. Harrwood Academic Publishers, Newark, NJ. A. Wright, B. Jay (Eds.).
29. Donders F.C. Beitrage zur patholgischen Anatomie des Auges. Albrecht von Graefes Arch Klin Exp Ophthalmol 1855, 18:106-118.
30. Drews R.C. The present understanding of cystoid macular edema. Trans Ophthalmol Soc U.K 1985, 104:744-747.
31. Feldman R.B., Mayo S.S., Robertson D.M., et al. Epiretinal membranes and cystoid macular edema in gyrate atrophy of the choroid and retina. Retina 1989, 9:139-142.
32. Fercher A.F., Mengedoht K., Werner W. Eye-length measurement by interferometry with partially coherent light. Opt Lett 1988, 13:186-188.
33. Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med 2010, 16:1107-1111.
34. Ferrone P.J., Trese M.T., Lewis H. Vitreoretinal surgery for complications of congenital retinoschisis. Am J Ophthalmol 1997, 123:742-747.
35. Ffytche T.J. Cystoid maculopathy in retinitis pigmentosa. Trans Ophthalmol Soc UK 1972, 92:265-283.
36. Fishman G.A., Anderson R.J., Lam B.L., et al. Prevalence of foveal lesions in type 1 and type 2 Usher's syndrome. Arch Ophthalmol 1995, 113:770-773.
37. Fishman G.A., Apushkin M.A. Continued use of dorzolamidefor the treatment of cystoid macular oedema inpatients with retinitis pigmentosa. Br J Ophthalmol 2007, 91:743-745.
38. Fishman G.A., Cunha-Vaz J., Salzano T. Vitreous fluorophotometry in patients with retinitis pigmentosa. Arch Ophthalmol 1981, 99:1202-1207.
39. Fishman G.A., Fishman M., Maggiano J. Macular lesions associated with retinitis pigmentosa. Arch Ophthalmol 1977, 95:798-803.
40. Fishman G.A., Gilbert L.D., Anderson R.J., et al. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology 1994, 101:687-693.
41. Fishman G.A., Gilbert L.D., Fiscella R.G., et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol 1989, 107:1445-1452.
42. Fishman G.A., Glenn A.M., Gilbert L.D. Rebound of macular edema with continued use of methazolamide in patients with retinitis pigmentosa. Arch Ophthal 1993, 111:1640-1646.
43. Fishman G.A., Jampol L.M., Goldberg M.F. Diagnostic features of the Favre-Goldmann syndrome. Br J Ophthalmol 1976, 60:345-353.
44. Fishman G.A., Kumar A., Joseph M.E., et al. Usher's syndrome. Ophthalmic and neuro-otologic findings suggesting genetic heterogeneity. Arch Ophthalmol 1983, 101:1367-1374.
45. Fishman G.A., Maggiano J.M., Fishman M. Foveal lesions seenin retinitis pigmentosa. Arch Ophthalmol 1977, 95:1993-1996.
46. Gabriele M.L., Wollstein G., Ishikawa H., et al. Optical coherence tomography: history, current status, and laboratory work. Invest Ophthalmol Vis Sci 2011, 52:2425-2436.
47. Ganesh A., Stroh E., Manayath G.J., et al. Macular cysts in retinal dystrophies. Curr Opin Ophthalmol 2011, 22:332-339.
48. García-Arumí J., Corcóstegui I.A., Navarro R., et al. Vitreoretinal surgery without schisis cavity excision for the management of juvenile X linked retinoschisis. Br J Ophthalmol 2008, 92:1558-1560.
49. Garcìa- Arumì J., Martinez V., Sararols L., et al. Vitreoretinalsurgery for cystoid macular edema associatedwith retinitis pigmentosa. Ophthalmology 2003, 110:1164-1169.
50. Garweg J., Bohnke M., Mangold I. Die behandlung desGoldmann-Favre-Syndroms mit cyclosporin A und Brimocriptin. Klin Mbl Augenheilk 1991, 199:199-205.
51. Gass J.D. Müller cell cone, an overlooked part of the anatomy of the fovea centralis:hypothesis concerning its role in the pathogenesis of macular hole and foveomacular retinoschisis. Arch Ophthamol 1999, 117:821-823.
52. Gass J.D. Stereoscopic Atlas of Macular Diseases. Diagnosis and Treatment 1997, MO, Mosby, St. Louis, p 1061. ed4.
53. Gass J.D., Norton E.D. Cystoid macular edema and papilledema following cataract extraction. Arch Ophthamol 1966, 76:646-661.
54. Gelişken O., Gelişken F., Ozçetin H. Treatment of chronic macular oedema with low dosage acetazolamide. Bull Soc Belge Ophtalmol 1990, 238:153-160.
55. Genead M.A., Fishman G.A. Cystic macular oedema on spectral-domain optical coherence tomography in choroidemia patients without cystic changes on fundus examination. Eye 2011, 25:84-90.
56. Genead M.A., Fishman G.A. Efficacy of topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and Usher syndrome. Arch Ophthalmol 2010, 128:1146-1150.
57. Genead M.A., Fishman G.A., McAnany J.J. Efficacy of topical dorzolamide for treatment of cystic macular lesions in a patient with enhanced S-cone syndrome. Doc Ophthalmol 2010, 121:231-240.
58. Genead M.A., Fishman G.A., Walia S. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Arch Ophthalmol 2010, 128:190-197.
59. Genead M.A., McAnany J.J., Fishman G.A. Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia. Retina 2012, 32:826-833.
60. George N.D., Yates J.R., Bradshaw K., et al. Infantile presentation of X-linked retinoschisis. Br J Ophthalmol 1995, 79:653-657.
61. George N.D., Yates J.R., Moore A.T. Clinical features in affected males with X-linked retinoschisis. Arch Ophthalmol 1996, 114:274-280.
62. Gerth C., Zawadzki R.J., Werner J.S., et al. Retinal morphological changes of patients with X-linked retinoschisis evaluated by Fourier-Domain optical coherence tomography. Arch Ophthalmol 2008, 126:807-811.
63. Ghajarnia M., Gorin M.B. Acetazolamide in the treatment of X-linked retinoshisis maculopathy. Arch Ophthalmol 2007, 125:571-573.
64. Ginsberg S. Uber retinitis pigmentosa. Klin Mbl Augenheik 1908, 46:1-10.
65. Gire A.I., Sullivan L.S., Bowne S.J., et al. The Gly56Arg mutation in NR2E3 accounts for 1-2% of autosomal dominant retinitis pigmentosa. Mol Vis 2007, 13:1970-1975.
66. Giusti C., Forte R., Vingolo E.M. Deflazacort treatment of cystoidmacular edema in patients affected by retinitis pigmentosa: a pilot study. Eur Rev Med Pharmacol Sci 2002, 6:1-8.
67. Gragoudas E.S., Adamis A.P., Cunningham E.T., et al. Pegaptanib for neovascular age-related macular degeneration. NEngl J Med 2004, 351:2805-2816.
68. Grayson C., Reid S.N., Ellis J.A., et al. Retinoschisin, the X-linked retinoschisis protein, is a secreted photoreceptor protein, and is expressed and released by Weri-Rb1 cells. Hum Mol Genet 2000, 9:1873-1879.
69. Gregori N.Z., Berrocal A.M., Gregori G., et al. Macular spectral-domain optical coherence tomography in patients with X linked retinoschisis. Br J Ophthalmol 2009, 93:373-378.
70. Grover S., Apushkin M.A., Fishman G.A. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 2006, 141:850-858.
71. Grover S., Fishman G.A., Fiscella R.G., et al. Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Retina 1997, 17:222-231.
72. Grunwald J.E., Mathur S., DuPont J. Effects of dorzolamide hydrochloride 2% on the retinal circulation. Acta Ophthalmol Scand 1997, 75:236-238.
73. Haas J. Ueber das Zusammenvorkommen von Veraenderungen der Retina und Chorioidea. Arch Augenheilkunde 1898, 37:343-348.
74. Hagiwara A., Yamamoto S., Ogata K., et al. Macular abnormalities in patients with retinitis pigmentosa: prevalence on OCT examination and outcomes of vitreoretinal surgery. Acta Ophthalmol 2011, 89:e122-e125.
75. Haider N.B., Jacobson S.G., Cideciyan A.V., et al. Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet 2000, 24:127-131.
76. Hajali M., Fishman G.A. The prevalence of cystoid macular oedema on optical coherence tomography in retinitis pigmentosa patients without cystic changes on fundus examination. Eye 2009, 23:915-919.
77. Hajali M., Fishman G.A., Anderson R.J. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol 2008, 92:1065-1068.
78. Hamada S., Yoshida K., Chihara E. Optical coherence tomography images of retinitis pigmentosa. Ophthalmic Surg Lasers 2000, 31:253-256.
79. Hartong D.T., Berson E.L., Dryja T.P. Retinitis pigmentosa. Lancet 2006, 368:1795-1809.
80. Heckenlively J.R., Jordan B.R., Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 1999, 127:565-573.
81. Heckenlively J.R., Solish A.M., Chant S.M., Meyers- Elliott R.H. Autoimmunity in hereditary retinal degenerations, II:clinical studies: antiretinal antibodies and fluorescein angiogram findings. Br J Ophthalmol 1985, 69:758-764.
82. Hee M.R., Puliafito C.A., Duker J.S., et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998, 105:360-370.
83. Hirakawa H., Iijima H., Gohdo T., et al. Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol 1999, 128:185-191.
84. Hope C.I., Bundey S., Proops D., et al. Usher syndrome in the city of Birmingham-prevalence and clinical classification. Br J Ophthalmol 1997, 81:46-53.
85. Hughes E.H., Schlichtenbrede F.C., Murphy C.C., et al. Generation of activated sialoadhesin-positive microglia during retinal degeneration. Invest Ophthalmol Vis Sci 2003, 44:2229-2234.
86. Hyvärinen L., Maumenee A.E., Kelley J., et al. Fluorescein angiographic findings in retinitis pigmentosa. Am J Ophthalmol 1971, 71(1 Pt 1):17-26.
87. Iannaccone A., Fung K.H., Eyestone M.E., et al. Treatment of adult-onset acute retinoschisis in enhanced-S cone syndrome with oral acetazolamide. Am J Ophthalmol 2009, 147:307-312.
88. Ikeda Y., Hisatomi T., Yoshida N., et al. The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2012, 250:809-814.
89. Ikeda F., Iida T., Kishi S. Resolution of retinoschisis after vitreous surgery in X-linked retinoschisis. Ophthalmology 2008, 115:718-722.
90. Jacobson S.G., Cideciyan A.V., Sumaroka A., et al. Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations. Invest Ophthalmol Vis Sci 2006, 47:4113-4120.
91. Joensuu T., Hamalainen R., Yuan B., et al. Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3. Am J Hum Genet 2001, 69:673-684.
92. Jonas J.B., Hayler A., Sofker J.K., et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2011, 131:468-471.
93. Kass M.A., Kolker A.E., Gordon M., et al. Acetazolamide and urolithiasis. Ophthalmology 1981, 88:261-265.
94. Kellner U., Brummer S., Foerster M.H., et al. X-linked congenital retinoschisis. Graefe's Archive Ophthalmol 1990, 228:432-437.
95. Khairallah M., Ladjimi A., Ben Yahia S., et al. Elevated macular retinoschisis associated with Goldmann-Favre syndrome successfully treated with grid laser photocoagulation. Retina 2002, 22:234-237.
96. Kimberling W.J., Hildebrand M.S., Shearer A.E., et al. Frequency of Usher syndrome in two pediatric populations: implications for genetic screening of deaf and hard of hearing children. Genet Med 2010, 12:512-516.
97. Kirsch L.S., Brownstein S., de Wolff-Rouendaal D. Ahistopatological ultrastructural and immunohistochemical study of congenital hereditary retinoschisis. Can Ophthalmol 1996, 31:301-310.
98. Kovack J.L., Rosenfeld P.J. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009, 29:27-32.
99. Kraushar M.F., Stepens C.L., Kaplan J.A., et al. Congenital retinoschisis. Contemporary Ophthamology Honoring Sir Stewart Duke-Elder 1972, 149-161. Williams and Wilkins, Baltimore, MD.
100. Kumar A., Babu M., Kimberling W.J., et al. Genetic analysis of a four generation Indian family with Usher syndrome: a novel insertion mutation in MYO7A. Mol Vis 2004, 10:910-916.
101. Larsen M., Engler C.B., Haim M., et al. Blood-retina barrier permeability is independent of trace substance lipid solubility in retinitis pigmentosa and in the healthy eye. Int Ophthalmol 1998, 21:229-234.
102. Luna G., Kjellstrom S., Verardo M.R., et al. The effects oftransient retinal detachment of cavity size and glialandneural remodelling in a mouse model of X-linkedretinoschisis. Invest Ophthalmol Vis Sci 2009, 50:3977-3984.
103. MacVicar J.E., Wilbrandt H.R. Hereditary retinoschisis and early hemeralopia. A report of two cases. Arch Ophthalmol 1970, 83:629-636.
104. Majid M.A., Horsborough B., Gray R.H. Unusal macular findingsin known choroideremia carrier. Eye 1998, 12(Pt 4):740-741.
105. Mallick K.S., Zeimer R.C., Fishman G.A., et al. Transport of fluorescein in the ocular posterior segment in retinitis pigmentosa. Arch Ophthalmol 1984, 102:691-696.
106. Marmor M.F., Maack T. Enhancement of retinal adhesion and sub-retinal fluid resorption by acetazolamide. Invest Ophthalmol Vis Sci 1982, 23:121-124.
107. McCulloch C. Choroideremia: a clinical and pathologic review. Trans Am Ophthalmol Soc 1969, 67:142-195.
108. Melo G.B., Farah M.E., Aggio F.B. Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthamol Scand 2007, 85:461-463.
109. Merin S. Macular cysts as an early sign of tapetoretinal degeneration. JPediatr Ophthalmol 1970, 7:225-228.
110. Milam A.H., Rose L., Cideciyan A.V., et al. The nuclear receptor NR2E3 plays a role in human retinal photoreceptor differentiation and degeneration. Proc Natl Acad Sci USA 2002, 99:473-478.
111. Minami Y., Ishiko S., Takai Y., et al. Retinal changes in juvenile X linked retinoschisis using three dimentional optical coherence tomography. Br J Ophthalmol 2005, 89:1663-1664.
112. Mincione F., Scozzafava A., Supuran C.T. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des 2008, 14:649-654.
113. Minnella A.M., Falsini B., Bamonte G., et al. Optical coherence tomography and focal electroretinogram evaluation of cystoid macular edema secondary to retinitis pigmentosa treated with intravitreal triamcinolone: Case report. Eur J Ophthalmol 2006, 16:883-886.
114. Molday R.S. Focus on molecules:retinoschisin (RS1). Exp Eye Res 2007, 84:227-228.
115. Molday L.L., Hicks D., Sauer C.G., et al. Expression of X-linked retinoschisis protein RS1 in photoreceptor and bipolar cells. Invest Ophthalmol Vis Sci 2001, 42:816-825.
116. Moldow B., Sander B., Larsen M., et al. The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular edema. Graefe Arch Clin Exp Ophthalmol 1998, 236:881-889.
117. Ness S.L., Ben-Yosef T., Bar-Lev A., et al. Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III. JMed Genet 2003, 40:767-772.
118. Newsome D.A. Retinal fluorescein leakage in retinitis pigmentosa. Am J Ophthalmol 1986, 101:354-360.
119. Newsome D.A., Blacharski P.A. Grid photocoagulation for macular edema in patients with retinitis pigmentosa. Am J Ophthamol 1987, 103:161-166.
120. Noll H. Zur Cosmistik der Lochbildunhgen in der Macula lutea: retinitis atrophicans centralis. Arch Augenheilkd 1908, 60:254-261.
121. Noyes H.D. Retinitis in glycosuria. Trans Am Ophthalmol Soc 1868, 1:71-75.
122. Nuel J.P. Alterations de la macula lutea:oedème maculaire ou pèrifovèal. Arch d'Ophthalmol 1896, 16:145-181.
123. O' Donnell J.J., Sandman R.P., Marting S.R. Gyrate atrophy of the retina:inborn error of L-ornithin:2-oxoacid aminotransferase. Science 1978, 200:200-201.
124. Ochrietor J.D., Clamp M.F., Moroz T.P., et al. Carbonic anhydrase XIV identified as the membrane CA in mouse retina: strong expression in Muller cells and the RPE. Exp Eye Res 2005, 81:492-500.
125. Oliveira T.L., Andrade R.E., Muccioli C., et al. Cystoid macular edema in gyrate atrophy of the choroid and retina: a fluorescein angiography and optical coherence tomography evaluation. Am J Ophthalmol 2005, 140:147-149.
126. Orzalesi N., Pierrottet C., Porta A., et al. Long-term treatment of retinitis pigmentosa with acetazolamide. A pilot study. Graefe's Arch Clin Exp Ophthalmol 1993, 231:254-256.
127. Ossewaarde-van N.J., Berg E.M., Sijssens K.M., et al. Subfoveal serous retinal detachment in patients with uveitic macular edema. Arch Ophthalmol 2011, 129:158-162.
128. Otani T., Kishi S., Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999, 127:688-693.
129. Ozdemir H., Karacorlu M., Karacorlu S. Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 2005, 83:248-251.
130. Pagenstecher H.E. Ueber eine unter dem Bilde der Natzhauterblosung verlaufende, erbliche Erkrankung der Retina. Graefes Arch Ophthalmol 1913, 86:457-462.
131. Pakarinen L., Karjalainen S., Simola K.O.J., et al. Usher's syndrome type 3 in Finland. Laryngoscope 1995, 105:613-617.
132. Peachey N.S., Fishman G.A., Derlacki D.J., et al. Psychophysical and electroretinographic findings in X-linked juvenile retinoschisis. Arch Ophthalmol 1987, 105:513-516.
133. Peltola K.E., Nanto-Salonen K., Heinonen O.J., et al. Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase. Ophthalmology 2001, 108:721-729.
134. Penfold P.L., Wen L., Madigan M.C., et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the EVC304 cell line implications for macular degenerations. Clin Exp Immunol 2000, 121:458-465.
135. Perry V.H., Crocker P.R., Gordon S. The blood-brain barrier regulates the expression of a macrophage sialic acid-binding receptor on microglia. JCell Sci 1992, 101(Pt 1):201-207.
136. Pimenides D., George N.D., Yates J.R., et al. X-linked retinoschisis: clinical phenotype and RS1 genotype in 86 UK patients. JMed Genet 2005, 42:e35.
137. Podoleanu A.G., Dobre G.M., Webb D.J., et al. Simultaneous en-face imaging of two layers in the human retina by low-coherence reflectometry. Opt Lett 1997, 22:1039-1041.
138. Potter M.J., Berson E.L. Diagnosis and treatment of gyrate atrophy. Int Ophthalmol Clin 1993, 33:229-236.
139. Preising M., Ayuso C. Rab escort protein 1 (REP1) in intracellular traffic: a functional and pathophysiological overview. Ophthalmic Genet 2004, 25:101-110.
140. Prenner J.L., Capone A., Ciaccia S., et al. Congenital X-linked retinoschisis classification system. Retina 2006, 27(7 Suppl):S61-S64.
141. Pruett R.C. Retinitis pigmentosa-clinical observations and correlations. Trans Am Ophthalmol Soc 1983, 81:693-735.
142. Querques G., Prascina F., Iaculli C., et al. Intravitreal pegabtanib sodium (Macugen) for refractory cystoid macular edema in pericentral retinitis pigmentosa. Int Ophthalmol 2009, 29:103-107.
143. Rao G.N., Cotlier E. Ornithine delta-aminotransferase acitivity in retina and other tissues. Neurochem Res 1984, 9:555-562.
144. Reichenbach A., Wurm A., Pannicke T., et al. Muller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol 2007, 245:627-636.
145. Renner A.B., Kellner U., Cropp E., et al. Choroideremia: variability of clinical and electrophysiological characteristics and first report of a negative electroretinogram. Ophthalmology 2006, 113. 2066.e1-10.
146. Richardson G.P., de Monvel J.B., Petit C. How the genetics of deafness illuminates auditory physiology. Annu Rev Physiol 2011, 73:311-334.
147. Richer S.P., Stiles W., Graham-Hoffman K., et al. Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. Optometry 2011, 82:667-680.
148. Roberts M.F., Fishman G.A., Roberts D.K., et al. Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia. Br J Ophthalmol 2002, 86:658-662.
149. Roller A.B., Folk J.C., Patel N.M., et al. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 2011, 31:1848-1855.
150. Sahel J., Bonnel S., Mrejen S., et al. Retinitis pigmentosa and other dystrophies. Dev Ophthalmol 2010, 47:160-167.
151. Sallum J.M., Farah M.E., Saraiva V.S. Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide: case report. Adv Exp Med Biol 2003, 533:79-81.
152. Salom D., Diaz-Llopis M., Garcìa- Delpech S., et al. Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa. JOcul Pharmacol Ther 2010, 26:531-532.
153. Sandberg M.A., Brockhurst R.J., Gaudio A.R., et al. Visual acuity is related to parafoveal retinal thickness in patients with retinitis pigmentosa and macular cysts. Invest Ophthalmol Vis Sci 2008, 49:4568-4572.
154. Saraiva V.S., Sallum J.M., Farah M.E. Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2003, 34:398-400.
155. Sasamoto Y., Gomi F., Sawa M., et al. Effect of 1-year lutein supplementation on macular pigment optical density and visual function. Graefes Arch Clin Exp Ophthalmol 2011, 249:1847-1854.
156. Sauer C.G., Gehrig A., Warneke-Wittstock R., et al. Positional cloning of the gene associated with X-linked juvenile retinoschisis. Nat Genet 1997, 17:164-170.
157. Scholl S., Augustin A., Loewenstein A., et al. General pathophysiology of macular edema. Eur J Ophthalmol 2011, 21(Suppl 6):10-19.
158. Schwartz S.B., Aleman T.S., Cideciyan A.V., et al. Disease expression in Usher syndrome caused by VLGR1 gene mutation (USH2C) and comparison with USH2A phenotype. Invest Ophthalmol Vis Sci 2005, 46:734-743.
159. Scorolli L., Morara M., Meduri A., et al. Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol 2007, 125:759-764.
160. Seabra M.C., Brown M.S., Goldstein J.L. Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. Science 1993, 259:377-381.
161. Sergouniotis P.I., Davidson A.E., Lenassi E., et al. Retinal structure, function, and molecular pathologic features in gyrate atrophy. Ophthalmology 2012, 119:596-605.
162. Shahidi M., Fishman G.A., Ogura Y., et al. Foveal thickening in retinitis pigmentosa patients with cystoid macular edema. Retina 1994, 14:243-247.
163. Sharma Y.R., Singh D.V., Azad R.V., et al. Gyrate atrophy with bilateral full thickness macular hole. Eye 2006, 20:745-747.
164. Sharon D., Sandberg M.A., Caruso R.C., et al. Shared mutations in NR2E3 in enhanced S-cone syndrome, Goldmann-Favre syndrome, and many cases of clumped pigmentary retinal degeneration. Arch Ophthalmol 2003, 121:1316-1323.
165. Sieving P.A., Bingham E.L., Kemp J., et al. Juvenile X-linked retinoschisis from XLRS1 Arg213Trp mutation with preservation of the electroretinogram scotopic b-wave. Am J Ophthalmol 1999, 128:179-184.
166. Sikkink S.K., Biswas S., Parry N.R., et al. X-linked retinoschis:an update. JMed Genet 2007, 44:225-232.
167. Sohn E.H., Chen F.K., Rubin G.S., et al. Macular function assessed by microperimetry in patients with enhanced S-cone syndrome. Ophthalmology 2010, 117:1199-1206.
168. Sorsby A., Franceschetti A., Joseph R., et al. Choroideremia; clinical and genetic aspects. Br J Ophthalmol 1952, 36:547-581.
169. Souied E.H., Goritsa A., Querques G., et al. Indocyanine green angiography of juvenile X-linked retinoschisis. Am J Ophthalmol 2005, 140:558-561.
170. Stanga P.E., Downes S.M., Ahuja R.M., et al. Comparison of optical coherence tomography and fluorescein angiography in assessing macular edema in retinal dystrophies:preliminary results. Int Ophthalmol 2001, 23:321-325.
171. Steiner-Champliaud M.F., Sahel J., Hicks D. Retinoschisin forms a multi-molecular complex with extracellular matrix and cytoplasmatic proteins:interactions with β2 laminin and αβ-crystallin. Mol Vis 2006, 12:892-901.
172. Steinmetz R.L., Fitzke F.W., Bird A.C. Treatment of cystoid macular edema with acetazolamide in a patient with serpiginouschoroidopathy. Retina 1991, 11:412-415.
173. Stock W. Ueber eine bis jetz noch nicht beschriebene form der familiär auftretenden netzhautdegeneration bei gleichzeitiger verblödung und über typische pigment-degeneration dei netzhaut. Klin Monatsbl Augenheilkd 1908, 46:225-244.
174. Takada Y., Fariss R.N., Tanikawa A., et al. Aretinal neuronal developmental wave of retinoschisin expression begins in ganglion cells during layer formation. Invest Ophthalmol Vis Sci 2004, 45:3302-3312.
175. Takezawa M., Tetsuka S., Kakehashi A. Tangential vitreous traction: a possible mechanism of development of cystoid macular edema in retinitis pigmentosa. Clin Ophthalmol 2011, 5:245-248.
176. Takki K., Simell O. Gyrate atrophy of the choroid and retina with hyperornithinemia HOGA. Birth Defects Orig Artic Ser 1976, 12:373-384.
177. The 103rd annual meeting of the Japanese Ophthalmological Society. Chiba City, Japan. April 21-24, 1999. Nihon Ganka Gakkai Zasshi 1999, 103(3 Suppl):1-219.
178. Thobani A., Fishman G.A. The use of carbonic anhydrase inhibitors in the retreatment of cystic macular lesions in retinitis pigmentosa and X-linked retinoschisis. Retina 2011, 31:312-315.
179. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011, 56:95-113.
180. Trese M.T., Ferrone P.J. The role of inner wall retinectomy in the management of juvenile retinoschisis. Graefes Arch Clin Exp Ophthalmol 1995, 233:706-708.
181. Tsilou E.T., Rubin B.I., Caruso R.C., et al. Usher syndrome clinical types I and II: could ocular symptoms and signs differentiate between the two types?. Acta Ophthalmol Scand 2002, 80:196-201.
182. Vannas-Sulonen K. Progression of gyrate atrophy of the choroid and retina. A long-term follow-up by fluorescein angiography. Acta Ophthalmol (Copenh) 1987, 65:101-109.
183. Vasconcelos-Santos, Magalhaes E.P., Nehemy M.B. Macular edema associated with gyrate atrophy managed with intravitreal triamcinolone: a case report. Arq Bras Oftalmol 2007, 70:858-861.
184. Verpy E., Leibovici M., Zwaenepoel I., et al. Adefect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrome type 1C. Nat Genet 2000, 26:51-55.
185. Vingolo E.M., Giusti C., Forte R., et al. Vitreal alterations in retinitis pigmentosa: biomicroscopic appearance and statistical evaluation. Ophthalmologica 1996, 210:104-107.
186. Vinores S.A., Derevjanik N.L., Ozaki H., et al. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol 1999, 97:217-228.
187. Vozzi D., Aaspõllu A., Athanasakis E., et al. Molecular epidemiology of Usher syndrome in Italy. Mol Vis 2011, 17:1662-1668.
188. Waldstein S.M., Hickey D., Mahmud I., et al. Two-wavelength fundus autofluorescence and macular pigment optical density imaging in diabetic macular oedema. Eye 2012, 26:1078-1085.
189. Walia S., Fishman G.A., Hajali M. Prevalence of cystic macular lesions in patients with Usher II syndrome. Eye 2009, 23:1206-1209.
190. Walia S., Fishman G.A., Molday R.S., et al. Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin. Am J Ophthalmol 2009, 147:111-115.
191. Weene L.E. Cystoid macular edema after scleral buckling responsive to acetazolamide. Ann Ophthalmol 1992, 24:423-424.
192. Weigert G., Kaya S., Pemp B., et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2011, 52:8174-8178.
193. Weiner Jm Diuretics and other agents employed in the mobilization of edema fluid 1990, 716-718. MacMillan, New York. A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.).
194. Wistrand P.J., Schenholm M., Lonnerholm G. Carbonic anhydrase isoenzymes CA I and CA II in the human eye. Invest Ophthamol Vis Sci 1986, 27:419-428.
195. Wolfensberger T.J. The historical discovery of macular edema. Doc Ophthalmol 1999, 97:207-216.
196. Wolfensberger T.J. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 1999, 97:387-397.
197. Wolfensberger T.J., Aptsiauri N., Godley B., et al. Antiretinal antibodies associated with cystoid macular edema. Klin Monatsbl Augenheilkd 2000, 216:283-285.
198. Wolfensberger T.J., Dmitriev A.V., Govardovskii V.I. Inhibition of membrane- bound carbonic anhydrase decreases subretinal pH and volume. Doc Ophthalmol 1999, 97:261-271.
199. Wolfensberger T.J., Mahieu I., Jarvis-Evans J., et al. Membrane-bound carbonic anhydrase in human retinal pigment epithelium. Invest Ophthalmol Vis Sci 1994, 35:3401-3407.
200. Wu W.C., Drenser K.A., Capone A., et al. Plasmin enzyme-assisted vitreoretinal surgery in congenital X-linked retinoschisis:surgical techniques bases on a new classification system. Retina 2007, 27:1079-1085.
201. Yanoff M., Rahn E.K., Zimmerman L.E. Histopathology of juvenile retinoschisis. Arch Ophthal 1968, 79:49-53.
202. Yassur Y., Nissenkorn I., Ben-Sira I., et al. Autosomal dominant inheritance of retinoschisis. Am J Ophthalmol 1982, 94:338-343.
203. Yuzbasioglu E., Artunay O., Rasier R., et al. Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa. Curr Eye Res 2009, 34:231-237.